Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2002 1
2004 1
2007 1
2017 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
The following term was not found in PubMed: /
Page 1
Pharmacokinetic/pharmacodynamic modeling of benazepril and benazeprilat after administration of intravenous and oral doses of benazepril in healthy horses.
Serrano-Rodríguez JM, Gómez-Díez M, Esgueva M, Castejón-Riber C, Mena-Bravo A, Priego-Capote F, Ayala N, Caballero JMS, Muñoz A. Serrano-Rodríguez JM, et al. Res Vet Sci. 2017 Oct;114:117-122. doi: 10.1016/j.rvsc.2017.03.016. Epub 2017 Mar 28. Res Vet Sci. 2017. PMID: 28371693 Clinical Trial.
Pharmacokinetic and pharmacodynamic (PK/PD) properties of the angiotensin-converting enzyme inhibitor (ACEI) benazeprilat have not been evaluated in horses. This study was designed to establish PK profiles for benazepril and benazeprilat after intravenous (IV …
Pharmacokinetic and pharmacodynamic (PK/PD) properties of the angiotensin-converting enzyme inhibitor (ACEI) benazeprilat have …
Pharmacokinetics and pharmacokinetic/pharmacodynamic relationships for angiotensin-converting enzyme inhibitors.
Toutain PL, Lefèbvre HP. Toutain PL, et al. J Vet Pharmacol Ther. 2004 Dec;27(6):515-25. doi: 10.1111/j.1365-2885.2004.00601.x. J Vet Pharmacol Ther. 2004. PMID: 15601445 Review.
The pharmacokinetic (PK) properties and the pharmacokinetic/pharmacodynamic (PK/PD) relationships for the angiotensin-converting enzyme (ACE) inhibitors (ACEIs), such as enalaprilat, benazeprilat, imidaprilat and ramiprilat, differ from those of conventional drugs. …
The pharmacokinetic (PK) properties and the pharmacokinetic/pharmacodynamic (PK/PD) relationships for the angiotensin-converting enzy …
Effect of renal insufficiency on the pharmacokinetics and pharmacodynamics of benazepril in cats.
King JN, Strehlau G, Wernsing J, Brown SA. King JN, et al. J Vet Pharmacol Ther. 2002 Oct;25(5):371-8. doi: 10.1046/j.1365-2885.2002.00427.x. J Vet Pharmacol Ther. 2002. PMID: 12423228 Clinical Trial.
The effect of renal insufficiency was studied on the pharmacokinetics (PK) and pharmacodynamics (PD) of the angiotensin-converting enzyme (ACE) inhibitor benazepril in cats. The active metabolite of benazepril, benazeprilat, is eliminated principally ( approximately …
The effect of renal insufficiency was studied on the pharmacokinetics (PK) and pharmacodynamics (PD) of the angiotensin-converting en …
Roles of vasoconstrictor prostaglandins, COX-1 and -2, and AT1, AT2, and TP receptors in a rat model of early 2K,1C hypertension.
Welch WJ, Patel K, Modlinger P, Mendonca M, Kawada N, Dennehy K, Aslam S, Wilcox CS. Welch WJ, et al. Am J Physiol Heart Circ Physiol. 2007 Nov;293(5):H2644-9. doi: 10.1152/ajpheart.00748.2007. Epub 2007 Aug 31. Am J Physiol Heart Circ Physiol. 2007. PMID: 17766473 Free article.

Compared with sham-operated rats, 2K,1C Goldblatt rats had increased mean arterial pressure (MAP; 120 +/- 4 vs. 155 +/- 3 mmHg; P < 0.001), plasma renin activity (PRA; 22 +/- 7 vs. 48 +/- 5 ng x ml(-1) x h(-1); P < 0.01), plasma malondialdehyde (1.07 +/- 0.05 vs. 1.58 +/- 0

…

Compared with sham-operated rats, 2K,1C Goldblatt rats had increased mean arterial pressure (MAP; 120 +/- 4 vs. 155 +/- 3 mmHg; P < 0.001

…
Structural adaptation to ischemia in skeletal muscle: effects of blockers of the renin-angiotensin system.
Scheidegger KJ, Nelissen-Vrancken MH, Leenders PJ, Daemen MJ, Smits JF, Wood JM. Scheidegger KJ, et al. J Hypertens. 1997 Dec;15(12 Pt 1):1455-62. doi: 10.1097/00004872-199715120-00013. J Hypertens. 1997. PMID: 9431852
Treatments with subhypotensive and with hypotensive doses of the angiotensin converting enzyme (ACE) inhibitor benazeprilat, the angiotensin (Ang) II AT1 antagonist valsartan, or the Ang II AT2 antagonist PD 123 319 for 4 weeks did not influence any of the above-des …
Treatments with subhypotensive and with hypotensive doses of the angiotensin converting enzyme (ACE) inhibitor benazeprilat, the angi …